HRSA To Lilly: Don’t Equate HHS’ Silence As Backing Your 340B Policy

By Michelle M. Stein / September 23, 2020 at 4:36 PM
The Health Resources and Services Administration on Monday (Sept. 21) told Eli Lilly and Company that it shouldn’t assume HHS agrees with its decision to end 340B pricing for drugs obtained through most contract pharmacies, and warned the drug maker it could face a lawsuit if HRSA finds the company “knowingly violates a material condition of the program that results in over-charges to grantees and contractors.” However, Helen Pfister, partner with Manatt, Phelps & Phillips, said HRSA’s letter doesn’t directly...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.